CTOs on the Move

MaxThera

www.maxthera.com

 
MaxThera, Inc. is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.maxthera.com
  • 100 Cummings Ctr Ste 419E
    Beverly, MA USA 01915
  • Phone: 978.927.8900

Executives

Name Title Contact Details

Similar Companies

Pharm-Olam

Pharm-Olam International is a multi-national contract research organization (CRO) offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.

Moog Medical

Moog Medical designs reliable and easy-to-use CURLIN infusion and Infinity enteral feeding pumps that allow our patients to live life more fully.

Afexa Life Sciences

Afexa Life Sciences Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Age Medical Center

New Age Medical Center Functional Medicine plays a vital role in our everyday lives and Dr. Moreno is committed to helping our patients achieve improved overall wellness. In addition to internal medicine, anti-aging procedures, and nutritional & wei...

Vernalis

Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.